TY  - JOUR
AU  - Sharma, Rohini
AU  - Alharbi, Sultan N
AU  - Ellum, Ksenia
AU  - Motedayen-Aval, Leila
AU  - Casadei-Gardini, Andrea
AU  - Pinato, David J
AU  - Bettinger, Dominik
AU  - Bengsch, Bertram
AU  - Patel, Rishi
AU  - Evans, Joanne
TI  - Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma.
JO  - npj precision oncology
VL  - 9
IS  - 1
SN  - 2397-768X
CY  - [London]
PB  - Springer Nature
M1  - DKFZ-2025-01336
SP  - 214
PY  - 2025
AB  - Survival following transarterial chemoembolisation (TACE) for hepatocellular cancer (HCC) is variable. We explored targeted sequencing of circulating tumour DNA (ctDNA) as a prognostic biomarker. Plasma samples (n = 97) were collected at baseline and following TACE. Targeted, ultra-deep sequencing was conducted on 18 somatic mutations related to the molecular pathogenesis of HCC. Median progression-free survival and overall survival were 11.6 months (95
LB  - PUB:(DE-HGF)16
C6  - pmid:40596669
C2  - pmc:PMC12218101
DO  - DOI:10.1038/s41698-025-00961-2
UR  - https://inrepo02.dkfz.de/record/302796
ER  -